// App-Quantinova.ai

: Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability

Researchers

Presenter

  • Anupam Verma

Principal Investigators

  • Karin Chen

  • Jacob Johnsen

  • Phillip Barnette

Medical Centers

  • Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT

  • Department of Pediatrics, Division of Allergy & Immunology, University of Utah, Salt Lake City, UT

  • Department of Pharmacy, Primary Childrens Hospital, Salt Lake City, UT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • asparaginase Erwinia chrysanthemi

  • Pegaspargase

  • Oncaspar

  • Asparaginase

  • Erwinase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved